Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, van den Meiracker AH, Saklayen MG, Oveisi S, Jardine AG, Delles C, Preiss DJ, Mark PB. Currie G, et al. Among authors: ohtsu h. BMC Nephrol. 2016 Sep 8;17(1):127. doi: 10.1186/s12882-016-0337-0. BMC Nephrol. 2016. PMID: 27609359 Free PMC article. Review.
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M, Yamada A, Fujita T; Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators. Ando K, et al. Among authors: ohtsu h. Hypertens Res. 2010 Jun;33(6):616-21. doi: 10.1038/hr.2010.46. Epub 2010 Apr 9. Hypertens Res. 2010. PMID: 20379190 Clinical Trial.
Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, Hirohama D, Kawakami-Mori F, Shibata S, Nagase M, Isshiki M, Oba S, Shimosawa T, Fujita T. Nishimoto M, et al. Among authors: ohtsu h. Hypertens Res. 2019 Apr;42(4):514-521. doi: 10.1038/s41440-018-0201-7. Epub 2019 Jan 11. Hypertens Res. 2019. PMID: 30631161
Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan.
Yoshihara F, Ohtsu H, Nakai M, Tsuzuki S, Hayakawa K, Terada M, Matsunaga N, Yasuda S, Ogawa H, Ohmagari N. Yoshihara F, et al. Among authors: ohtsu h. J Cardiol. 2022 Oct;80(4):292-297. doi: 10.1016/j.jjcc.2022.04.001. Epub 2022 Apr 8. J Cardiol. 2022. PMID: 35469713 Free PMC article.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Among authors: ohtsu h. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S; J-RHYTHM II Investigators. Yamashita T, et al. Among authors: ohtsu h. Europace. 2011 Apr;13(4):473-9. doi: 10.1093/europace/euq439. Epub 2010 Dec 10. Europace. 2011. PMID: 21148662 Clinical Trial.
Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.
Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, Okumura K, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E; J-RHYTHM II Investigators. Yamashita T, et al. Among authors: ohtsu h. Circ J. 2006 Oct;70(10):1318-21. doi: 10.1253/circj.70.1318. Circ J. 2006. PMID: 16998266 Free article. Clinical Trial.
359 results